News
TMDX
73.94
-0.24%
-0.18
TransMedics draws bullish view at Piper Sandler on valuation
Healthcare TransMedics draws bullish view at Piper Sandler on valuation on valuation of organ care company. The firm says the company is trading seven times over its 2024 earnings and has a compelling valuation compared to its peers. Piper has an Overweight rating and a $95 price target on the company's stock.
Seeking Alpha · 6h ago
Cracking The Code: Understanding Analyst Reviews For TransMedics Gr
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients. The company has an average price target of $100.0. TransMedics Gr's 12-month price targets reflect an increase of 18.11% from the previous average. 4 analysts have released ratings for the company in the past three months.
Benzinga · 9h ago
TransMedics Group Initiated at Overweight by Piper Sandler
Dow Jones · 11h ago
TransMedics Group Price Target Announced at $95.00/Share by Piper Sandler
Dow Jones · 11h ago
Piper Sandler Initiates Coverage On TransMedics Gr with Overweight Rating, Announces Price Target of $95
Benzinga · 11h ago
TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating
TipRanks · 3d ago
Weekly Report: what happened at TMDX last week (0318-0322)?
Weekly Report · 3d ago
TransMedics Group (TMDX) Shares Cross Below 200 DMA
NASDAQ · 6d ago
TransMedics: Strong Business, Fully Valued Stock
TransMedics is a rapidly growing provider of organ transplant services, including perfusion devices and transportation. The company has achieved rapid growth on the back of technology which improves the utilization of organs. TransMedics' valuation is relatively high, creating substantial downside risk. The stock should continue to perform reasonably well though due to growth and the transition to profitability.
Seeking Alpha · 6d ago
TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Seeking Alpha · 03/19 05:46
Weekly Report: what happened at TMDX last week (0311-0315)?
Weekly Report · 03/18 10:19
TransMedics Group: Huge Opportunity In Organ Transplants
TransMedics Group is transforming the organ transplant landscape. The company has led to double-digit growth in liver, lung, and heart transplants in the U.S. With a market size of over $1.5 billion in 2023. TransMedics has a proven technology, FDA approved, and is a rare early-stage investment opportunity in organ transplants.
Seeking Alpha · 03/12 18:14
Weekly Report: what happened at TMDX last week (0304-0308)?
Weekly Report · 03/11 10:17
Transmedics Group: Statement of changes in beneficial ownership of securities
Press release · 03/06 02:53
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
NASDAQ · 03/04 11:20
Weekly Report: what happened at TMDX last week (0226-0301)?
Weekly Report · 03/04 10:19
Jim Cramer Recommends Buying Wayfair, Says This Big Bank's Stock Yields Almost 3%
Jim Cramer said he likes Bank of America Corporation. The "Mad Money" host recommended buying Wayfair Inc. And TransMedics Group, Inc. He said organ transplants are important and the company is doing well. Cramer also said he's ok with WESCO International.
Benzinga · 02/29 13:47
Cracking The Code: Understanding Analyst Reviews For TransMedics Gr
Analysts' ratings for TransMedics Gr over the last quarter vary from bullish to bearish. The company is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients. Analysts have set 12-month price targets for the company of $95.0 and $105.00. The average price target has risen by 23.38% over the past quarter.
Benzinga · 02/28 19:01
TransMedics Group Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 02/28 18:19
Morgan Stanley Maintains Equal-Weight on TransMedics Gr, Raises Price Target to $95
Benzinga · 02/28 18:09
More
Webull provides a variety of real-time TMDX stock news. You can receive the latest news about Transmedics Group through multiple platforms. This information may help you make smarter investment decisions.
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.